KR920701145A - 신규의 비타민 d 유사체 - Google Patents
신규의 비타민 d 유사체Info
- Publication number
- KR920701145A KR920701145A KR1019910700655A KR910700655A KR920701145A KR 920701145 A KR920701145 A KR 920701145A KR 1019910700655 A KR1019910700655 A KR 1019910700655A KR 910700655 A KR910700655 A KR 910700655A KR 920701145 A KR920701145 A KR 920701145A
- Authority
- KR
- South Korea
- Prior art keywords
- pregna
- seco
- triene
- formula
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (12)
- 일반식(Ⅰ)의 화합물 및 이의 유도체상기식에서, R은 하이드록시 그룹에 의해 임의로 치환된 탄소수 4내지 12의 알킬 그룹이고, 일반식(Ⅰ)화합물의 유동체인 경우, 한개 이상의 하이드록시 그룹은 생체내에서 가수분해가능한 차페 그룹인 -O- 아실 또는 -O-글리코실 또는 에스테르인산염 그룹으로 전환된다.
- 제1항에 있어서, R이 일반식(Ⅱ)의 그룹인 화합물.상기식에서, n은 1내지 7의 정수이고, R1및 R2는 동일하거나 상이하며, 수소 C1-C5-알킬, C3-C7-사이클로알킬이거나, X, R1및 R2가 결합되는 탄소원자(일반식(Ⅱ)에서 *로 표시부분)와 함께 C3-C8카보사이클릭환을 형성하며, X는 수소 또는 하이드록시이다.
- 제1항 또는 제2항에 있어서, 순수한 형태의 디아스테레오이성체, 또는 제1항 또는 제2항의 화합물의 디아스테레오이성체의 혼합물.
- 제1항에 있어서, 하기(a)내지 (h)로부터 선택되는 화합물 : a)1(S),3(R)-디하이드록시-20(R)-(4'-하이드록시-4'-에틸-1'-헥실옥시)-9, 10-세코-프레그나-5(Z),7(E),10(19)-트리엔 b)1(S),3(R)-디하이드록시-20(R)-(6'-하이드록시-1'-헥실옥시)-9, 10-세코-프레그나-5(Z),7(E),10(19)-트리엔, c)1(S),3(R)-디하이드록시-20(R)-(5'-하이드록시-5'-에틸-1'-헵틸옥시)-9, 10-세코-프레그나-5(Z),7(E),10(19)-트리엔, d)1(S),3(R)-디하이드록시-20(R)-(5'-하이드록시-5'-메틸-1'-헥실옥시)-9, 10-세코-프레그나-5(Z),7(E),10(19)-트리엔, e)1(S),3(R)-디하이드록시-20(R)-(5'-메틸-1'-헥틸옥시)-9, 10-세코-프레그나-5(Z),7(E),10(19)-트리엔, f)1(S),3(R)-디하이드록시-20(R)-(4'-하이드록시-4'-(1″-프로필)-1'-헵틸옥시)-9, 10-세코-프레그나-5(Z),7(E),10(19)-트리엔, g)1(S),3(R)-디하이드록시-20(R)-(4'-하이드록시-4'-메틸-1'-펜틸옥시)-9, 10-세코-프레그나-5(Z),7(E),10(19)-트리엔, h)1(S),3(R)-디하이드록시-20(R)-(3'-하이드록시-3'-메틸-1'-부틸옥시)-9, 10-세코-프레그나-5(Z),7(E),10(19)-트리엔.
- a)1(S),3(R)-비스-(3급-부틸디메틸실릴옥시)-20(S)-포밀-9, 10-세코-프레그나-5(E),7(E),10(19)-트리엔을 염기성 촉매의 존재하에 산소로 산화시켜, 1(S),3(R)-비스-(3급-부틸디메틸실릴옥시)-9,10-세코-프레그나-5(E),7(E),10(19)-트리엔-20-온을 생성시키고; b)1(S),3(R)-비스-(3급-부틸디메틸실릴옥시)-9, 10-세코-프레그나-5(E),7(E),10(19)-트리엔-20-올을 예를 들면, 봉수소화 나트륨을 환원시켜, 1(S),3(R)-비스-(3급-부틸디메틸실릴옥시)-9,10-세코-프레그나-5(E),7(E),10(19)-트리엔-20-온을 생성시키고; c)1(S),3(R)-비스-(3급-부틸디메틸실릴옥시)-9, 10-세코-프레그나-5(E),7(E),10(19)-트리엔-20(R)-올을 염기성 조건하에 일반식 Z-R3(여기에서, Z는 할로겐, p-톨루엔설 포닐옥시 또는 메탄설포닐옥시와 같은 이탈 그룹이다)의 측쇄 빌딩 블록으로 알킬화시켜 하기 일반식(Ⅲ)의 화합물(여기에서, R3는 상기에서 정의된 R 또는 이의 유사체이거나, R로 전환될 수 있는 임의의 라디칼이다)을 생성시키고;d)상기 일반식(Ⅲ)의 화합물을 삼중-감응된 광이성체화 시키고, 필요하다면, R3를 R로 전환시키고 탈보호화하여, 제1항에 따른 일반식(Ⅰ)의 목적 화합물 또는 이의 유사체를 생성시키는 단계를 사용하여, 제1항에 따른 일반식(Ⅰ)의 화합물을 제조하는 방법.
- 1(S),3(R)-비스-(3급-부틸디메틸실릴옥시)-9,10-세코-프레그나-5(E),7(E),10(19)-트리엔-20(R)-올인 일반식(Ⅰ)의 화합물 및 이의 유사체 합성을 위한 중간 산물.
- 유효량의 제1항에 따른 화합물 하나 이상 및 약제학적으로 허용되는, 비-유독성 담체 및/또는 보조제를 함유하는 약제학적 조성물.
- 제7항에 있어서, 용량 단위형의 약제학적 조성물.
- 일반식(Ⅰ)의 화합물 0.05 내지 50ug, 바람직하게는 0.1 내지 25ug을 함유하는 제8항에 따른 용량 단위투여형.
- 당뇨병, 고혈압, 염증성 질환(예 : 류마치스 관절염 및 천식), 및 비정상적 세포 분화 및/또는 세포 증식 현상을 특징으로 하는 질환을 포함하는 자가면역성 질환 및/또는 면역시스템의 불균형 상태를 치료 및 예방하기 위한 방법.
- 제10항에 있어서, 암을 치료 또는 예방하기 위한 방법.
- 제10항에 있어서, 건선을 치료하기 위한 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB898904154A GB8904154D0 (en) | 1989-02-23 | 1989-02-23 | Chemical compounds |
GB89041545 | 1989-02-23 | ||
GB8904154.5 | 1989-02-23 | ||
PCT/DK1990/000036 WO1990009991A1 (en) | 1989-02-23 | 1990-02-13 | Novel vitamin d analogues |
SG131794A SG131794G (en) | 1989-02-23 | 1994-09-12 | Novel vitamin D analogues |
Publications (2)
Publication Number | Publication Date |
---|---|
KR920701145A true KR920701145A (ko) | 1992-08-11 |
KR0163194B1 KR0163194B1 (ko) | 1999-01-15 |
Family
ID=26295003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019910700655A KR0163194B1 (ko) | 1989-02-23 | 1990-02-13 | 비타민d 유사체 |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP0460032B1 (ko) |
JP (1) | JP2807083B2 (ko) |
KR (1) | KR0163194B1 (ko) |
AT (1) | ATE104957T1 (ko) |
AU (1) | AU627001B2 (ko) |
CA (1) | CA2044280C (ko) |
DE (1) | DE69008517T2 (ko) |
DK (1) | DK0460032T3 (ko) |
ES (1) | ES2055905T3 (ko) |
FI (1) | FI92929C (ko) |
GB (1) | GB8904154D0 (ko) |
HK (1) | HK128894A (ko) |
HU (1) | HU211025B (ko) |
IE (1) | IE63123B1 (ko) |
LT (1) | LT3983B (ko) |
LV (1) | LV10428B (ko) |
NO (1) | NO178065C (ko) |
PT (1) | PT93232B (ko) |
RO (1) | RO109939B1 (ko) |
RU (1) | RU2037484C1 (ko) |
SG (1) | SG131794G (ko) |
WO (1) | WO1990009991A1 (ko) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8904153D0 (en) * | 1989-02-23 | 1989-04-05 | Leo Pharm Prod Ltd | Chemical compounds |
DE4011682A1 (de) * | 1990-04-06 | 1991-10-10 | Schering Ag | 24-oxa-derivate in der vitamin d-reihe |
GB9015774D0 (en) * | 1990-07-18 | 1990-09-05 | Leo Pharm Prod Ltd | Novel treatment |
US5486509A (en) * | 1991-06-28 | 1996-01-23 | University Of Miami | Method of preventing and treating chemotherapy-induced alopecia |
AU666563B2 (en) * | 1992-08-07 | 1996-02-15 | Wisconsin Alumni Research Foundation | Preparation of 19-nor-vitamin D compounds |
GB9220272D0 (en) * | 1992-09-25 | 1992-11-11 | Leo Pharm Prod Ltd | Chemical compounds |
GB9220439D0 (en) * | 1992-09-28 | 1992-11-11 | Leo Pharm Prod Ltd | Chemical compounds |
US5449668A (en) * | 1993-06-04 | 1995-09-12 | Duphar International Research B.V. | Vitamin D compounds and method of preparing these compounds |
US5945410A (en) | 1997-03-17 | 1999-08-31 | Wisconsin Alumni Research Foundation | 2-alkyl-19-nor-vitamin D compounds |
US6306844B1 (en) | 1997-03-17 | 2001-10-23 | Wisconsin Alumni Research Foundation | Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength |
US6316642B1 (en) | 1997-03-17 | 2001-11-13 | Wisconsin Alumni Research Foundation | 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds |
US6392071B1 (en) | 1997-03-17 | 2002-05-21 | Wisconsin Alumni: Research Foundation | 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds |
US6359152B2 (en) | 1997-07-21 | 2002-03-19 | Wisconsin Alumni Research Foundation | 18-substituted-19-nor-vitamin D compounds |
US5939406A (en) * | 1997-07-21 | 1999-08-17 | Wisconsin Alumni Research Foundation | 18-substituted-19-nor-vitamin D compounds |
US5962707A (en) * | 1998-08-18 | 1999-10-05 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D3 compounds with calcemic activity |
US7074777B2 (en) | 2000-04-19 | 2006-07-11 | Chugai Seiyaku Kabushiki Kaisha | Vitamin D derivatives |
US20030018017A1 (en) * | 2001-01-25 | 2003-01-23 | Deluca Hector F. | Method of treatment of type I diabetes |
US20060293291A1 (en) | 2003-04-10 | 2006-12-28 | Deluca Hector F | 2-Propylidene-19-nor-vitamin d compounds |
US6894037B2 (en) | 2003-07-03 | 2005-05-17 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses |
US7713951B2 (en) | 2004-04-09 | 2010-05-11 | Wisconsin Alumni Research Foundation | 2-alkylidene-18,19-dinor-vitamin D compounds |
WO2006051106A1 (en) | 2004-11-12 | 2006-05-18 | Bioxell Spa | Combined use of vitamin d derivatives and anti-proliferative agents for treating bladder cancer |
NZ571896A (en) | 2006-04-05 | 2011-09-30 | Wisconsin Alumni Res Found | 1-Alpha.-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D compounds and methods of making and use thereof |
US8377913B2 (en) * | 2007-11-20 | 2013-02-19 | Abbvie Inc. | Vitamin D receptor activators and methods of making |
JP5563324B2 (ja) * | 2010-02-03 | 2014-07-30 | フォーモサ・ラボラトリーズ・インコーポレーテッド | マキサカルシトール中間体およびその製造方法 |
WO2012122451A2 (en) | 2011-03-09 | 2012-09-13 | Teva Pharmaceutical Industries Ltd. | Polymorphs of maxacalcitol and process for the preparation of maxacalcitol |
CN102796134B (zh) * | 2012-08-31 | 2015-07-01 | 甘肃皓天化学科技有限公司 | 一种马沙骨化醇中间体的制备方法 |
CN103910666A (zh) * | 2014-04-15 | 2014-07-09 | 湖南华腾制药有限公司 | 一种制备马沙骨化醇的方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0078704B1 (en) | 1981-11-02 | 1987-04-29 | Research Institute For Medicine And Chemistry Inc. | Intermediates in the synthesis of vitamin d derivatives |
DE3577552D1 (de) * | 1984-11-27 | 1990-06-13 | Chugai Pharmaceutical Co Ltd | Vitamin d-derivate und verfahren zu deren herstellung. |
EP0227826B1 (en) | 1985-08-02 | 1989-10-25 | Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) | Novel vitamin d analogues |
AU614372B2 (en) | 1988-04-21 | 1991-08-29 | Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) | Novel vitamin d analogues |
GB8904153D0 (en) * | 1989-02-23 | 1989-04-05 | Leo Pharm Prod Ltd | Chemical compounds |
-
1989
- 1989-02-23 GB GB898904154A patent/GB8904154D0/en active Pending
-
1990
- 1990-02-13 CA CA002044280A patent/CA2044280C/en not_active Expired - Fee Related
- 1990-02-13 AT AT9090903793T patent/ATE104957T1/de not_active IP Right Cessation
- 1990-02-13 DE DE69008517T patent/DE69008517T2/de not_active Expired - Fee Related
- 1990-02-13 KR KR1019910700655A patent/KR0163194B1/ko not_active IP Right Cessation
- 1990-02-13 DK DK90903793.9T patent/DK0460032T3/da active
- 1990-02-13 WO PCT/DK1990/000036 patent/WO1990009991A1/en active IP Right Grant
- 1990-02-13 JP JP2504126A patent/JP2807083B2/ja not_active Expired - Fee Related
- 1990-02-13 RO RO148060A patent/RO109939B1/ro unknown
- 1990-02-13 AU AU51983/90A patent/AU627001B2/en not_active Ceased
- 1990-02-13 ES ES90903793T patent/ES2055905T3/es not_active Expired - Lifetime
- 1990-02-13 EP EP90903793A patent/EP0460032B1/en not_active Expired - Lifetime
- 1990-02-13 HU HU902300A patent/HU211025B/hu not_active IP Right Cessation
- 1990-02-22 PT PT93232A patent/PT93232B/pt not_active IP Right Cessation
-
1991
- 1991-06-19 IE IE42190A patent/IE63123B1/en not_active IP Right Cessation
- 1991-07-25 NO NO912902A patent/NO178065C/no not_active IP Right Cessation
- 1991-08-12 FI FI913812A patent/FI92929C/fi active
- 1991-08-22 RU SU915001741A patent/RU2037484C1/ru not_active IP Right Cessation
-
1993
- 1993-09-28 LV LVP-93-1106A patent/LV10428B/en unknown
- 1993-12-06 LT LTIP1536A patent/LT3983B/lt not_active IP Right Cessation
-
1994
- 1994-09-12 SG SG131794A patent/SG131794G/en unknown
- 1994-11-17 HK HK128894A patent/HK128894A/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR920701145A (ko) | 신규의 비타민 d 유사체 | |
KR920701148A (ko) | 비타민 d 동족체 | |
US5246925A (en) | 19-nor-vitamin D compounds for use in treating hyperparathyroidism | |
US5561123A (en) | Method of treating proliferative skin disorders with 19-nor-vitamin D compounds | |
KR920703527A (ko) | 신규한 비타민 d 동족체 | |
KR950703501A (ko) | 신규한 비타민 D 동족체(Novel vitamin D analogues) | |
CA2588396A1 (en) | 17,20(e)-dehydro vitamin d analogs and their uses | |
KR100195573B1 (en) | Novel vitamin d analogues | |
DK0460034T3 (da) | Nye D-vitaminanaloger | |
KR950701909A (ko) | 신규한 비타민D 동족체(Novel vitamin D analogues) | |
AU8407282A (en) | Carbocyclic prostacyclin alcohol analogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20010724 Year of fee payment: 4 |
|
LAPS | Lapse due to unpaid annual fee |